MR-Vac

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, GlaxoSmithKline Biologicals

Conditions

DiarrhoeaMalariaMalaria PaediatricsMalaria Vaccines

Phase 2

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

CompletedNCT06663436

GlaxoSmithKlineDiarrhoea

Start: 2024-11-13End: 2025-10-21Updated: 2026-01-30

Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

CompletedNCT02699099

GlaxoSmithKlineMalaria, Malaria Vaccines

Start: 2017-05-10End: 2020-10-07Updated: 2021-09-29

Unknown Phase

Immunogenicity & safety of GSK Biologicals malaria vaccine given at 6,7.5 &9 months of age coadministered with measles,rubella & yellow fever vaccines

Active, not recruitingPACTR201602001483150

GlaxoSmithKline BiologicalsMalaria Paediatrics

Start: 2016-09-14Target: 700Updated: 2026-01-27

Related Papers

Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.

2020-03-1710 citations